← Browse by Condition

Medical Condition

glioblastoma

Total Trials

27

Recruiting Now

27

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for glioblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — glioblastoma Clinical Trials

How many clinical trials are currently recruiting for glioblastoma?

ClinicalMetric currently tracks 27 actively recruiting clinical trials for glioblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 27. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for glioblastoma?

glioblastoma research spans Phase 1 (12 trials), Phase 2 (8 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a glioblastoma clinical trial?

Eligibility criteria for glioblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

12

Phase 2

8

Top Sponsors

Peter Siesjö 2 trials

Telix Pharmaceuticals (Innovations) Pty Limited 1 trial

Kailin Yang, MD, PhD 1 trial

Jasper Gerritsen 1 trial

Jonsson Comprehensive Cancer Center 1 trial

Recruiting Clinical Trials

NCT05450744 Phase 1

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

Australia, Austria, ...

Telix Pharmaceuticals (Innovat...

NCT07541781 Phase 1

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Kailin Yang, MD, PhD

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

United States, Belgi...

Jasper Gerritsen

NCT07089641 Phase 1

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Jonsson Comprehensive Cancer C...

NCT05917145 Phase 1

ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma

NCT07551336 Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Beijing Biotech

NCT06710249 Phase 2

Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema

NCT03603405 Phase 1, Phase 2

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

The Methodist Hospital Researc...

Preoperative Preradiotherapy TTFields

The Christie NHS Foundation Tr...

NCT06991101 Phase 2

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Baptist Health South Florida

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques

Amsterdam UMC, location VUmc

Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients

First Affiliated Hospital, Sun...

NCT06161519 Phase 1, Phase 2

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

National Cancer Institute (NCI...

Restrictive Use of Dexamethasone in Glioblastoma

Insel Gruppe AG, University Ho...

NCT05590689 Phase 1, Phase 2

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor

Universität Münster

NCT06645808 EARLY_Phase 1

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Var2 Pharmaceuticals

NCT03383978 Phase 1

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Johann Wolfgang Goethe Univers...

Drug Response Testing and Repurposing Using Glioblastoma Organoid

Chungnam National University H...

The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections

United States, Belgi...

Erasmus Medical Center

NCT04863950 Phase 2

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

The University of Texas Health...

NCT05463848 Phase 2

Surgical Pembro +/- Olaparib w TMZ for rGBM

L. Nicolas Gonzalez Castro, MD...

NCT05106296 Phase 1

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Theodore S. Johnson

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

Medical University of Warsaw

Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma

Beta Emitting Accurate Monitor...

NCT05432518 EARLY_Phase 1

Pilot Trial for Treatment of Recurrent Glioblastoma

AHS Cancer Control Alberta

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

City of Hope Medical Center

NCT07364786 Phase 2

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

Related Conditions

recurrent glioblastoma (5) glioblastoma multiforme (3) glioma (2) glioblastoma idh wildtype (2) glioblastoma multiforme of brain (2) glioblastoma multiforme adult (2) medulloblastoma (2) ependymoma (2) lung carcinoma (2) neoplastic disease (1) recurrent glioma (1) grade 4 malignant glioma of brain disorder (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology